

Company profile

Fact Sheet (Status: May 17, 2012)

Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of application of immunology and haematology. The most important starting material for our pharmaceutical products is human blood plasma which we process into effective and highly pure medicinal products in one of the world's most modern production facilities. In its Plasma Protein segment, Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells.

Biotest products meet the highest standards and are sold in markets which have to satisfy the most stringent registration requirements in the world. Patients, hospitals, medical practices, laboratories and companies in more than 160 countries around the globe put their trust in Biotest's quality and safety. Biotest has more than 1,600 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.


Management board

- Prof. Dr. Gregor Schulz (C)
- Dr. Michael Ramroth

Supervisory board

- Dr. Alessandro Banchi
- Dr. Cathrin Schleussner
- Herr Jürgen Heilmann
- Kerstin Birkhahn
- Thomas Jakob
- Dr. Christoph Schröder

Share chart of ordinary shares



Shareholder structure of ordinary shares

Release according to § 21 Abs. 1 WpHG

50.03%	OGEL GmbH
24.36%	Kreissparkasse Biberach

The voting rights stated below should be assigned to the companies according to § 22 Abs.1 Satz 1 Nr. 6 WpHG:

7.43%	BWInvest Baden-Württembergische Investmentgesellschaft mbH, Stuttgart
4.63%	BayernInvest Kapitalanlage-gesellschaft mbH
4.47%	Deka Investment GmbH, Frankfurt

Stock fundamentals of ordinary shares

ISIN	DE0005227201
WKN	522 720
Share type	Ordinary
Reuters Code	BIOG_p.DE
Bloomberg Code	BIO@GR
Ticker	BIO

Branch	Pharma
Country	Deutschland
Index	Prime All Share
Segment	Prime Standard
Last Dividend	EUR 0.38 (for 2010)
No. of shares	6,595,242

Stock exchanges	Regulierter Markt in Frankfurt; Open Market in Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart
Rating	-

Share chart of preferred shares

Shareholder structure of preferred shares



100,00% Free float

Stock fundamentals of preferred shares

ISIN	DE0005227235
WKN	522 723
Share type	Preferred
Reuters Code	BIOG_p.DE
Bloomberg Code	BIO@GR
Ticker	BIO

Branch	Pharma
Country	Deutschland
Index	SDAX
Segment	Prime Standard
Last Dividend	EUR 0.44 (for 2010)
No. of shares	5,133,333

Stock exchanges	Regulierter Markt in Frankfurt; Open Market in Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart
-----------------	--

Rating

Financial calendar

Mar 22, 2012	Annual Press Conference
Mar 22, 2012	Publication of Annual Report
May 10, 2012	Annual General Meeting
May 10, 2012	Publication of Q1 Report
Aug 13, 2012	Publication of Q2 Report
Nov 13, 2012	Publication of Q3 Report
Nov 13, 2012	Analysts' Conference

FACT SHEET



Key figures

Annual figures	2007	2008	2009 ²⁾	2010 ³⁾	2011
in EUR millions ¹⁾					
Sales	326.4	423.0	440.2	412.5	422.0
EBITDA	54.9	81.8	87.4	69.8	72.4
EBIT	38.5	55.6	61.5	42.9	41.6
Profit before tax	30.2	40.5	49.0	28.4	28.6
Net profit	15.5	25.7	31.9	19.6	18.7
Balance Sheet Total	536.7	592.0	633.5	632.3	682.8
Shareholders' equity	225.8	253.4	269.9	307.6	346.7
Dividend in EUR					
Ordinary	0.30	0.30	0.34	0.38	0.44
Preference	0.36	0.36	0.40	0.44	0.50
Staff	1,727	1,952	1,834	1,611	1,662

Quarterly figures	2009 ²⁾			2010 ³⁾			2011 ³⁾			2012 ³⁾
in EUR millions ¹⁾	Q1	Q2	Q3	Q1	Q2	Q3	Q1	Q2	Q3	Q1
Sales	119.4	119.8	122.7	115.0	112.1	115.2	106.5	106.4	99.0	107.7
EBIT	14.4	15.0	15.8	12.3	11.4	11.5	9.1	10.9	10.1	10.4
Profit before tax	11.2	12.2	12.6	10.2	10.2	2.8	6.6	8.3	5.3	7.3
Profit after tax	7.7	8.3	9.1	7.5	7.1	1.2	4.4	7.3	27.3	3.8
Balance Sheet Total	613.5	629.7	644.5	636.9	656.1	640.5	637.9	680.8	721.9	689.5
Shareholders' equity	264.0	264.5	269.1	297.7	308.5	300.7	308.6	307.9	339.8	348.1
Staff	2,064	2,099	2,135	1,830	1,851	1,854	1,627	1,649	1,670	1,688

¹⁾ all figures according to IFRS/IAS

²⁾ Continuing Operations after disposal of the transfusion and transplantation activities to Bio-Rad Laboratories, Inc.

³⁾ Continuing Operations after disposal of the transfusion and transplantation activities to Bio-Rad Laboratories, Inc. and the microbiological Monitoring to Merck KGaA

Biotest AG

Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland

Tel: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-8 80
E-Mail:
investor_relations@biotest.de
<http://www.biotest.de>

Investor Relations

Dr. Monika Buttke
Head of Investor Relations
investor_relations@biotest.de

Telefon: +49 (0) 61 03 / 801 4406
Telefax: +49 (0) 61 03 / 801 347